Literature DB >> 22315329

Rapid sequence induction and intubation with rocuronium-sugammadex compared with succinylcholine: a randomized trial.

M K Sørensen1, C Bretlau, M R Gätke, A M Sørensen, L S Rasmussen.   

Abstract

BACKGROUND: An unanticipated difficult airway may arise during rapid sequence induction and intubation (RSII). The aim of the trial was to assess how rapidly spontaneous ventilation could be re-established after RSII. We hypothesized that the time period from tracheal intubation to spontaneous ventilation would be shorter with rocuronium-sugammadex than with succinylcholine.
METHODS: This randomized and patient- and observer-blinded trial was approved by the regional Ethics Committee and the Danish Medicines Agency. We included elective surgical patients undergoing general anaesthesia for RSII using alfentanil (10 µg kg(-1)), propofol (2 mg kg(-1)), and either succinylcholine (1 mg kg(-1)) or rocuronium (1 mg kg(-1)). Sugammadex (16 mg kg(-1)) was given in the rocuronium group after tracheal intubation. The primary endpoint was the time from correct placement of the tracheal tube to spontaneous ventilation, defined as a respiratory rate of more than 8 bpm and a tidal volume of at least 3 ml kg(-1) for 30 s.
RESULTS: We included 61 patients; of whom, 55 were evaluated for the primary endpoint. The median time from tracheal intubation to spontaneous ventilation was 406 s with succinylcholine and 216 s with rocuronium-sugammadex (P = 0.002). The median time from tracheal intubation to 90% recovery of the first twitch in train-of-four (T(1) 90%) was 518 s with succinylcholine and 168 s with rocuronium-sugammadex (P < 0.0001). Intubation conditions and time to tracheal intubation were not significantly different.
CONCLUSIONS: RSII with rocuronium followed by reversal with sugammadex allowed earlier re-establishment of spontaneous ventilation than with succinylcholine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22315329     DOI: 10.1093/bja/aer503

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  28 in total

Review 1.  Rethinking general anesthesia for cesarean section.

Authors:  Hiroyiki Sumikura; Hidetomo Niwa; Masaki Sato; Tatsuo Nakamoto; Takashi Asai; Satoshi Hagihira
Journal:  J Anesth       Date:  2015-11-19       Impact factor: 2.078

2.  [Rapid sequence induction and intubation in patients with risk of aspiration : Recommendations for action for practical management of anesthesia].

Authors:  C Eichelsbacher; H Ilper; R Noppens; J Hinkelbein; T Loop
Journal:  Anaesthesist       Date:  2018-06-29       Impact factor: 1.041

Review 3.  Management of the patient presenting for emergency laparotomy.

Authors:  C Ilyas; J Jones; S Fortey
Journal:  BJA Educ       Date:  2019-02-04

4.  Fading Sugammadex, or Just Cautiously (re) Considered?!

Authors:  Sanda-Maria Copotoiu
Journal:  J Crit Care Med (Targu Mures)       Date:  2015-06-05

5.  Sugammadex: An Update.

Authors:  Tiberiu Ezri; Mona Boaz; Alexander Sherman; Marwan Armaly; Yitzhak Berlovitz
Journal:  J Crit Care Med (Targu Mures)       Date:  2016-02-09

Review 6.  Fibreoptic intubation in airway management: a review article.

Authors:  Jolin Wong; John Song En Lee; Theodore Gar Ling Wong; Rehana Iqbal; Patrick Wong
Journal:  Singapore Med J       Date:  2018-07-16       Impact factor: 1.858

Review 7.  Rocuronium versus succinylcholine for rapid sequence induction intubation.

Authors:  Diem T T Tran; Ethan K Newton; Victoria A H Mount; Jacques S Lee; George A Wells; Jeffrey J Perry
Journal:  Cochrane Database Syst Rev       Date:  2015-10-29

Review 8.  Anaesthetic management of acute airway obstruction.

Authors:  Patrick Wong; Jolin Wong; May Un Sam Mok
Journal:  Singapore Med J       Date:  2016-03       Impact factor: 1.858

9.  Sugammadex.

Authors:  Dennis J Cada; Terri L Levien; Danial E Baker
Journal:  Hosp Pharm       Date:  2016-07

10.  Emergency Neurological Life Support: Airway, Ventilation, and Sedation.

Authors:  Venkatakrishna Rajajee; Becky Riggs; David B Seder
Journal:  Neurocrit Care       Date:  2017-09       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.